EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

A systematic review of dalbavancin efficacy as a sequential therapy for infective endocarditis

Gabriele Maria Leanza, Emanuele Rando, Federico Frondizi, Eleonora Taddei, Francesca Giovannenze, Juan P Horcajada, Giancarlo Scoppettuolo, Carlo Torti

Infection · 2025-02 · 53 (1) · 15-23

DOI: 10.1007/s15010-024-02393-9 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Infection, online erschienen am 26.09.2024. Verfasst von Gabriele Maria Leanza und 7 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Sicurezza e Bioetica - Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy. Hauptthemen laut MEDLINE: Teicoplanin, Anti-Bacterial Agents, Endocarditis, Endocarditis, Bacterial. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università Cattolica del Sacro Cuore.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Dalbavancin is an antibiotic characterized by an extended half-life and efficacy against methicillin-resistant Staphylococci . Currently, there are only narrative reviews summarizing the evidence about the use of dalbavancin for infective endocarditis (IE), many of which are focused primarily on its use as consolidation therapy. For this reason, we conducted a systematic review to describe the clinical efficacy and the safety of dalbavancin in IE treatment.

Methods

We searched for available evidence using the MEDLINE (PubMed), Embase, Scopus, Cochrane Library and Web of Science libraries, with no restrictions regarding the publication year. The risk of bias was performed using the Cochrane ROBINS-I tool for the comparative studies and the Newcastle-Ottawa Scale for descriptive studies.

Results

Nine studies were included. All of them were observational. Native valve endocarditis was the most common kind of IE found in the studies’ populations (128/263, 48.7%), followed by prosthetic valve endocarditis, and cardiovascular implantable electronic device-related endocarditis. Coagulase-negative Staphylococci were the most common pathogens isolated (83/269, 30.1%), followed by S. aureus , Enterococci spp and Streptococci spp. Five out of nine studies documented a clinical failure rate of less than 10%. Dalbavancin showed a favourable safety profile. Dalbavancin appears to be a promising option for the consolidation therapy of IE. However, further studies comparing dalbavancin with standard of care are needed. PROSPERO registration number CRD42023430032.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TeicoplaninAnti-Bacterial AgentsEndocarditisEndocarditis, BacterialHumansTreatment Outcome

Stichwörter der Autor:innen

DalbavancinGram-positiveInfective endocarditisLong acting antibioticsSequential therapy

Substanzen

TeicoplanindalbavancinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Dipartimento di Sicurezza e Bioetica - Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Dipartimento di Sicurezza e Bioetica - Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy. federico.frondizi@guest.policlinicogemelli.it.
  • Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Hospital del Mar. Hospital del Mar Research Institute, Pompeu Fabra University (UPF), Barcelona, SpainCIBER of Infectious Diseases (CIBERINFEC CB21/13/00002), Institute of Health Carlos III, Madrid, Spain.

Förderung

  • Università Cattolica del Sacro Cuore

Zitieren

APA

Leanza, G. M., Rando, E., Frondizi, F., Taddei, E., Giovannenze, F., Horcajada, J. P., Scoppettuolo, G., & Torti, C. (2025). A systematic review of dalbavancin efficacy as a sequential therapy for infective endocarditis. Infection, 53(1), 15-23. https://doi.org/10.1007/s15010-024-02393-9

Vancouver

Leanza GM, Rando E, Frondizi F, Taddei E, Giovannenze F, Horcajada JP, et al. A systematic review of dalbavancin efficacy as a sequential therapy for infective endocarditis. Infection. 2025;53(1):15-23. doi:10.1007/s15010-024-02393-9

BibTeX
@article{Leanza2025,
  author = {Leanza, Gabriele Maria and Rando, Emanuele and Frondizi, Federico and Taddei, Eleonora and Giovannenze, Francesca and Horcajada, Juan P and Scoppettuolo, Giancarlo and Torti, Carlo},
  title = {A systematic review of dalbavancin efficacy as a sequential therapy for infective endocarditis},
  journal = {Infection},
  year = {2025},
  volume = {53},
  number = {1},
  pages = {15--23},
  doi = {10.1007/s15010-024-02393-9}
}
Kostenlos starten →